RayStation® is set to play a key role in the introduction of proton therapy in the Netherlands.
RayStation has been selected as the treatment planning solution for the Holland Particle Therapy Centre (HollandPTC), the first proton therapy center to be established in the Netherlands. The facility will open in August 2017 and expects to treat around 600 patients per year using the Varian ProBeam® System. The new center will mean that patients in the Netherlands no longer have to travel abroad to receive proton therapy.
Outstanding capabilities for proton planning, based on proven, innovative technology, make RayStation the solution of choice for many of the leading proton therapy centers worldwide. HollandPTC selected RayStation over other market-leading alternatives following an extensive tender process. RayStation received the highest assessment in a number of key areas, including adaptive therapy, connectivity, automation and scripting, user experience, and plan optimization. Next-generation plan optimization was an important area for HollandPTC, and RayStation’s multi-criteria optimization made the system a clear leader.
Delivery of the treatment planning solution will begin in the third quarter of 2016, with functionality including pencil beam scanning, adaptive therapy, radiobiology and multi-criteria optimization. The agreement includes both clinical and research licenses.
As well as supporting world-class patient care, RayStation will play an important role as a platform for pioneering research. The research partnership will cover areas such as adaptive therapy (online and offline), automated multi-criteria optimization, range verification and radiobiologically guided therapies.
Martijn Eenink, Medical Physicist at HollandPTC and Leiden University Medical Center, says: “We are excited about the opportunities RayStation offers for delivering state-of-the-art patient care. RayStation’s multi-criteria optimization will facilitate the production of treatment plans of the highest quality. The integrated support for image-guided proton therapy will allow us to easily adapt these plans to changes in patient anatomy during the course of treatment, thereby enhancing treatment accuracy.”
Johan Löf, CEO of RaySearch Laboratories, says: “Proton therapy is an important area of focus for RaySearch, and we have designed RayStation to deliver on its therapeutic possibilities. We have also ensured that RayStation can be used to create treatment plans for all relevant proton therapy machines on the market, and this of course includes the Varian ProBeam. I’m excited about the opportunity to both support clinical excellence at HollandPTC and drive development through this partnership.”
About proton therapy
Proton therapy is a cutting-edge radiation therapy technique that is growing in popularity worldwide. Its benefits include the ability to deliver maximum dose at a very precise depth in the body, with significantly less irradiation of healthy tissue.
HollandPTC is a partnership between Erasmus University Medical Center, Leiden University Medical Center and the Delft University of Technology. In addition to patient care, the center will provide education and conduct an extensive research and development program.
RayStation integrates all RaySearch’s advanced treatment planning solutions into a flexible treatment planning system. It combines unique features such as multi-criteria optimization tools with full support for 4D adaptive radiation therapy. It also includes functionality such as RaySearch’s market-leading algorithms for IMRT and VMAT optimization and highly accurate dose engines for photon, electron, proton and carbon ion therapy. The system is built on the latest software architecture and features a graphical user interface with state-of-the-art usability.
RaySearch Laboratories is a medical technology company that develops advanced software solutions for improved radiation therapy of cancer. RaySearch markets the RayStation treatment planning system to clinics all over the world. In addition, RaySearch’s products are distributed through licensing agreements with leading medical technology companies. RaySearch’s software is used by over 2,600 clinics in more than 65 countries. RaySearch was founded in 2000 as a spin-off from Karolinska Institutet in Stockholm, and the company is listed in the Mid Cap segment on NASDAQ OMX Stockholm.
To learn more about RaySearch, go to: www.raysearchlabs.com
For further information, please contact:
Johan Löf, President and CEO, RaySearch Laboratories AB (publ)
Telephone: +46 (0)8-510 530 00